Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 1
2012 1
2013 2
2014 1
2015 2
2016 3
2018 2
2020 6
2021 11
2022 18
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.
Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS. Strickler JH, et al. Among authors: bajor d. N Engl J Med. 2023 Jan 5;388(1):33-43. doi: 10.1056/NEJMoa2208470. Epub 2022 Dec 21. N Engl J Med. 2023. PMID: 36546651 Free PMC article. Clinical Trial.
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Strickler JH, et al. Among authors: bajor dl. Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. Lancet Oncol. 2023. PMID: 37142372 Clinical Trial.
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Byrne KT, et al. Among authors: bajor dl. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10. Clin Cancer Res. 2021. PMID: 34112709 Free PMC article. Clinical Trial.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Coveler AL, Smith DC, Phillips T, Curti BD, Goel S, Mehta AN, Kuzel TM, Markovic SN, Rixe O, Bajor DL, Gajewski TF, Gutierrez M, Lee HJ, Gopal AK, Caimi P, Heath EI, Thompson JA, Ansari S, Jacquemont C, Topletz-Erickson A, Zhou P, Schmitt MW, Grilley-Olson JE. Coveler AL, et al. Among authors: bajor dl. J Immunother Cancer. 2023 Jun;11(6):e005584. doi: 10.1136/jitc-2022-005584. J Immunother Cancer. 2023. PMID: 37385724 Free PMC article. Clinical Trial.
Neutrophil extracellular traps induced by chemotherapy inhibit tumor growth in murine models of colorectal cancer.
Li Y, Wu S, Zhao Y, Dinh T, Jiang D, Selfridge JE, Myers G, Wang Y, Zhao X, Tomchuck S, Dubyak G, Lee RT, Estfan B, Shapiro M, Kamath S, Mohamed A, Huang SC, Huang AY, Conlon R, Krishnamurthi S, Eads J, Willis JE, Khorana AA, Bajor D, Wang Z. Li Y, et al. Among authors: bajor d. J Clin Invest. 2024 Jan 9;134(5):e175031. doi: 10.1172/JCI175031. J Clin Invest. 2024. PMID: 38194275 Free PMC article.
CD40 immunotherapy for pancreatic cancer.
Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL. Vonderheide RH, et al. Among authors: bajor dl. Cancer Immunol Immunother. 2013 May;62(5):949-54. doi: 10.1007/s00262-013-1427-5. Epub 2013 Apr 16. Cancer Immunol Immunother. 2013. PMID: 23589109 Free PMC article. Review.
Clinical development of IDH1 inhibitors for cancer therapy.
Zarei M, Hue JJ, Hajihassani O, Graor HJ, Katayama ES, Loftus AW, Bajor D, Rothermel LD, Vaziri-Gohar A, Winter JM. Zarei M, et al. Among authors: bajor d. Cancer Treat Rev. 2022 Feb;103:102334. doi: 10.1016/j.ctrv.2021.102334. Epub 2021 Dec 28. Cancer Treat Rev. 2022. PMID: 34974243 Review.
The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience.
Mohamed A, Asa SL, Lee Z, Tirumani SH, Li Q, Avril N, Bajor D, Mahipal A, Chakrabarti S, Selfridge JE, Kardan A. Mohamed A, et al. Among authors: bajor d. J Gastrointest Oncol. 2023 Apr 29;14(2):1087-1094. doi: 10.21037/jgo-22-1011. Epub 2023 Mar 31. J Gastrointest Oncol. 2023. PMID: 37201086 Free PMC article. Review.
Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles Received, Cumulative Dose Intensity, and Survival in Resected Early-stage Pancreas Cancer.
Wu VS, Elshami M, Stitzel HJ, Lee JJ, Hue JJ, Kyasaram RK, Hardacre JM, Ammori JB, Winter JM, Selfridge JE, Mohamed A, Chakrabarti S, Bajor D, Mahipal A, Ocuin LM. Wu VS, et al. Among authors: bajor d. Ann Surg. 2023 Oct 1;278(4):e677-e684. doi: 10.1097/SLA.0000000000005830. Epub 2023 Feb 21. Ann Surg. 2023. PMID: 37071769
56 results